Open AccessThe first Japanese biobank of patient‐derived pediatric acute lymphoblastic leukemia xenograft models
Author(s) -
Tanaka Kuniaki,
Kato Itaru,
Dobashi Yuu,
Imai Junichi,
Mikami Takashi,
Kubota Hirohito,
Ueno Hiroo,
Ito Mamoru,
Ogawa Seishi,
Nakahata Tatsutoshi,
Takita Junko,
Toyoda Hidemi,
Ogawa Chitose,
Adachi Souichi,
Watanabe Shinya,
Goto Hiroaki
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15506
Subject(s) - biobank , medicine , lymphoblastic leukemia , oncology , pediatric cancer , childhood cancer , preclinical testing , nod , translational research , cancer , bioinformatics , cancer research , leukemia , pathology , medical physics , biology , diabetes mellitus , endocrinology
A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient‐derived xenografts (PDXs) in NOD.Cg‐ Prkdc scid ll2rg tm1Sug /ShiJic (NOG) mice and created a biobank by preserving PDX cells including three extramedullary relapsed ALL PDXs. We demonstrated that our PDX mice and PDX cells mimicked the biological features of relapsed ALL and that PDX models reproduced treatment‐mediated clonal selection. Our PDX biobank is a useful scientific resource for capturing drug sensitivity features of pediatric patients with ALL, providing an essential tool for the development of targeted therapies.